LH
Therapeutic Areas
Neumora Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Navacaprant | Major Depressive Disorder | Phase 3 |
| NMRA-511 | Agitation in Alzheimer's Disease | Phase 2 |
| NMRA-861 | Schizophrenia | Phase 1 |
| NMRA-898 | Schizophrenia | Preclinical |
| NMRA-215 | Obesity / Parkinson's Disease | Discovery |
| NMRA-GCASE | Parkinson's Disease | Discovery |
| NMRA-CK1δ | ALS / Parkinson's Disease | Discovery |
Leadership Team at Neumora Therapeutics
PL
Paul L. Berns
Chief Executive Officer
CS
Carol Suh
Chief Strategy Officer
NB
Nick Brandon
Chief Scientific Officer
JP
Joshua Pinto
President
BA
Bill Aurora
Chief Operating & Development Officer
AS
Amy Sullivan
Chief Human Resources Officer
JD
Jason Duncan
Chief Legal & Administrative Officer
MM
Michael Milligan
Chief Financial Officer
PG
Pablo Gersberg
Chief Information Officer